Know Cancer

or
forgot password

Program for Assessment of Capecitabine (Xeloda) Plus Docetaxel First-line Therapies in HER2-negative Metastatic Breast Cancer (XEBRA Study)


N/A
18 Years
N/A
Open (Enrolling)
Both
Breast Cancer

Thank you

Trial Information

Program for Assessment of Capecitabine (Xeloda) Plus Docetaxel First-line Therapies in HER2-negative Metastatic Breast Cancer (XEBRA Study)


Inclusion Criteria:



- Adult patients, >/= 18 years of age

- HER2-negative metastatic breast cancer

- Patients initiated on first-line therapy with Xeloda and docetaxel in accordance with
the Summary of Product Characteristics; patients who started treatment with Xeloda
and docetaxel no more than 3 months before enrollment in this study are also eligible

Exclusion Criteria:

- Contraindications to Xeloda treatment according to the Summary of Product
Characteristics

Type of Study:

Observational

Study Design:

Observational Model: Cohort, Time Perspective: Prospective

Outcome Measure:

Progression-free survival, defined as time from enrollment until disease progression or death of any cause

Outcome Time Frame:

approximately 3 years

Safety Issue:

No

Principal Investigator

Clinical Trials

Investigator Role:

Study Director

Investigator Affiliation:

Hoffmann-La Roche

Authority:

Hungary: National Institute of Pharmacy

Study ID:

ML28505

NCT ID:

NCT01777945

Start Date:

December 2012

Completion Date:

July 2015

Related Keywords:

  • Breast Cancer
  • Breast Neoplasms

Name

Location